To validate the tumor killing effect of CAR-T cells, we first designed and generated anti-MLSN CAR-T cells with a highly efficient second-generation human-derived scFv targeting MSLN, which was screened from a human-derived scFv phage display library (Figure 1A). The gene discussed is MSLN; the disease is neoplasm.